Christian M Lange1, Christoph Sarrazin, Stefan Zeuzem. Show Affiliations » 1. Universitätsklinik Lausanne, Schweiz.
Abstract
Entities: Disease
Mesh： See more » Antiviral Agents/adverse effectsAntiviral Agents/therapeutic useClinical Trials, Phase II as TopicDrug Resistance, ViralDrug Therapy, CombinationHepatitis C, Chronic/drug therapyHumansInterferon-alpha/adverse effectsInterferon-alpha/therapeutic useOligopeptides/adverse effectsOligopeptides/therapeutic useProline/adverse effectsProline/analogs & derivativesProline/therapeutic useProtease Inhibitors/therapeutic useViral Nonstructural Proteins/antagonists & inhibitorsVirus Replication/drug effects
Substances： See more » Antiviral AgentsInterferon-alphaNS3 protein, hepatitis C virusOligopeptidesProtease InhibitorsViral Nonstructural ProteinstelaprevirN-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamideProline
Year: 2011 PMID： 21194084 DOI： 10.1002/pauz.201100401
Source DB: PubMed Journal: Pharm Unserer Zeit ISSN： 0048-3664